Alexion CEO Ludwig Hantson (file photo)

Alex­ion bags a dis­count biotech buy­out for $1.4B, branch­ing out in new di­rec­tions from its Soliris fran­chise

Alex­ion is tak­ing a trip down to the dis­count base­ment for its next M&A deal. And this time the ex­ec­u­tive team wants to branch out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.